IDO1 and metastatic melanoma: This active immunotherapeutic strategy has been also validated in a clinical trial, in which patients with metastatic melanoma were treated with a combinatorial IDO/PD-L1-targeting approach based on IDO1-peptide vaccine combined with nivolumab [180].